



## Erratum

### Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1—Erratum

Jeffrey R. Scott, PharmD<sup>1\*</sup>, Joshua D. Courter, PharmD<sup>1</sup>, Shannon N. Saldaña, PharmD, MS, BCPP<sup>1–3\*</sup>, Brigitte C. Widemann, MD<sup>5</sup>, Michael Fisher, MD<sup>6</sup>, Brian Weiss, MD<sup>3,4</sup>, John Perentesis, MD<sup>3,4</sup>, Alexander A. Vinks, PharmD, PhD<sup>2,3¶</sup>

<sup>1</sup>Division of Pharmacy, Cincinnati Children's Hospital Medical Center

<sup>2</sup>Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center

<sup>3</sup>Department of Pediatrics, University of Cincinnati, College of Medicine

<sup>4</sup>Cancer & Blood Disease Institute, Division of Oncology, Cincinnati Children's Hospital Medical Center

<sup>5</sup> Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD

<sup>6</sup> Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA

on behalf of the Neurofibromatosis Clinical Trials Consortium.

\* at the time of study. Current affiliation: Department of Pharmacy, St. Jude Children's Research Hospital.

Send correspondence and/or reprint requests to: Alexander Vinks, PharmD, PhD, Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, OH 45229-3039, Sander.vinks@cchmc.org, Fax: (513) 803-8959, Phone: (513) 636-3833

Acknowledgements: Part of this work was supported by Department of Defense grant W81XWH-05-615, Neurofibromatosis Clinical Trials Consortium (B.W., M.F., B.W., J.P.P., A.V.V) and National Institutes of Health grant 5K24HD050387 (A.V.V.). Special thanks to the colleagues and staff of the STOPN study performed through the NF1 Clinical Trials Consortium.

The authors have noted some errors appearing in Table 2 on page 334 of the article that appeared in the June issue of 2013. A revised table is included below.

**Table 2**

## Sirolimus Dose and Population Pharmacokinetic Parameter Estimates

Population Results			
	Mean (SD)	Median (range)	Interquartile range
Clearance (L/hr)	11.8 (4.6)	11.6 (2.2–24.1)	8.5–14.4
Clearance (L/hr/70kg)	23.7 (6.7)	23.2 (8.4–48.8)	20.0–27.0
Clearance (L/hr/pop median wt)	9.9 (2.8)	9.7 (3.5–20.3)	8.4–11.3
Clearance (L/hr/1.85m <sup>2</sup> )	21.9 (5.4)	22.2 (8.1–37.7)	18.5–24.7
Therapeutic Dose (mg/m <sup>2</sup> /dose)	2.0 (0.7)	1.9 (0.77–3.9)	1.52–2.41
Therapeutic Dose (mg/kg/dose)	0.08 (0.04)	0.07 (0.02–0.19)	0.06–0.09
Therapeutic dose ((mg/kg) <sup>0.75</sup> )	0.14 (0.05)	0.13 (0.06–0.29)	0.11–0.16

## Reference:

Scott JR, Courter JD, Saldaña SN, et al. Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. *Ther Drug Monit.* 2013;35:332–337.